Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tricaprilin in infantile spasms
NCT04727970Phase 1Completed
- Sponsor
- Cerecin
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tricaprilin in infantile epileptic spasms syndrome (IESS), sponsored by Cerecin. Primary endpoints: Safety of daily administration, Tolerability of daily administration and 1 more. Started Nov 2021; status: completed.
02
Drugs
tricaprilin
03
Conditions
infantile epileptic spasms syndrome (IESS)
Beyond the preview
Go deeper on NCT04727970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727970.